Nanotechnology in the management of cervical cancer.
Cervical cancer is a major disease with high mortality. All cervical cancers are caused by infection with human papillomaviruses (HPV). Although preventive vaccines for cervical cancer are successful, treatment of cervical cancer is far less satisfactory because of multidrug resistance and side effects. In this review, we summarize the recent application of nanotechnology to the diagnosis and treatment of cervical cancer as well as the development of HPV vaccines. Early detection of cervical cancer enables tumours to be efficiently removed by surgical procedures, leading to increased survival rate. The current method of detecting cervical cancer by Pap smear can only achieve 50% sensitivity, whereas nanotechnology has been used to detect HPVs with greatly improved sensitivity. In cervical cancer treatment, nanotechnology has been used for the delivery of anticancer drugs to increase treatment efficacy and decrease side effects. Nanodelivery of HPV preventive and therapeutic vaccines has also been investigated to increase vaccine efficacy. Overall, these developments suggest that nanoparticle-based vaccine may become the most effective way to prevent and treat cervical cancer, assisted or combined with some other nanotechnology-based therapy.
Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia; School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia.
Jiezhong
J
Chen
Wenyi
W
Gu
Lei
L
Yang
Chen
C
Chen
Renfu
R
Shao
Kewei
K
Xu
Zhi Ping
ZP
Xu
D000818:Animals; D005260:Female; D006801:Humans; D036103:Nanotechnology / Q000295:instrumentation / Q000379:methods*; D027383:Papillomaviridae / Q000235:genetics / Q000502:physiology*; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000628:therapy* / Q000821:virology